Opko Health Inc. (NASDAQ:OPK) CEO Acquires $22,640.01 in Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 14,239 shares of Opko Health stock in a transaction that occurred on Tuesday, February 11th. The shares were bought at an average price of $1.59 per share, for a total transaction of $22,640.01. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $4,879,632.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, February 13th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were bought at an average price of $1.57 per share, for a total transaction of $157,000.00.
  • On Thursday, February 6th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $1.58 per share, for a total transaction of $79,000.00.
  • On Thursday, January 30th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were bought at an average price of $1.42 per share, for a total transaction of $142,000.00.
  • On Thursday, January 23rd, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $1.63 per share, for a total transaction of $81,500.00.
  • On Friday, January 17th, Phillip Md Et Al Frost purchased 22,262 shares of Opko Health stock. The shares were bought at an average price of $1.56 per share, for a total transaction of $34,728.72.
  • On Monday, January 13th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $1.44 per share, for a total transaction of $72,000.00.
  • On Friday, January 10th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $1.48 per share, for a total transaction of $74,000.00.
  • On Wednesday, January 8th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $73,500.00.
  • On Monday, December 30th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $147,000.00.
  • On Friday, December 27th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were bought at an average price of $1.49 per share, for a total transaction of $149,000.00.

Opko Health stock opened at $1.57 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.90 and a debt-to-equity ratio of 0.14. Opko Health Inc. has a 1 year low of $1.33 and a 1 year high of $2.88. The company has a market cap of $1.04 billion, a PE ratio of -3.27 and a beta of 2.39. The company’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.73.

A number of institutional investors have recently added to or reduced their stakes in OPK. State Street Corp lifted its position in Opko Health by 27.4% during the 4th quarter. State Street Corp now owns 17,898,336 shares of the biotechnology company’s stock valued at $26,311,000 after purchasing an additional 3,853,461 shares during the period. Marshall Wace LLP lifted its position in Opko Health by 557,260.0% during the 4th quarter. Marshall Wace LLP now owns 2,547,135 shares of the biotechnology company’s stock valued at $3,749,000 after purchasing an additional 2,546,678 shares during the period. Farallon Capital Management LLC acquired a new position in Opko Health during the 4th quarter valued at about $3,675,000. Nuveen Asset Management LLC acquired a new position in Opko Health during the 2nd quarter valued at about $4,789,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Opko Health during the 4th quarter valued at about $1,610,000. Institutional investors own 21.75% of the company’s stock.

Several brokerages recently issued reports on OPK. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Friday, October 18th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine upgraded shares of Opko Health from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, Piper Jaffray Companies assumed coverage on shares of Opko Health in a research report on Monday, November 25th. They set an “overweight” rating and a $2.50 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and an average target price of $2.83.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Read More: Market Perform

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.